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Case presentations
Patient 1. A 23-year-old female school teacher was referred to the
Tulane Medical School in New Orleans, Louisiana, 32 years ago, because
of chronic glomerulonephritis and progressive uremia. Her history in-
cluded acute glomerulonephritis at age 14 and persistent proteinuria
thereafter. She had been asymptomatic until three months prior to
admission, when she experienced weakness and dizziness. Physical exam-
ination was unremarkable, apart from a blood pressure of 190/120mm Hg.
Laboratory studies showed BUN, 184 mg/dl; creatinine, 40 mg/dl; and
creatinine clearance, 4 mI/mm. The patient's condition deteriorated
rapidly and was managed by peritoneal dialysis.
In 1963, a living-related or cadaveric renal transplant was not an option
for her management, and chronic dialysis facilities were unavailable
locally. Faced with these limitations in management of several patients,
the physicians in charge, Keith Reemtsma and Oscar Creech, had begun
a transplant program using chimpanzee kidney donors. Selection of the
donor was based on body size and blood typing of the donor and recipient
(chimpanzees are either blood type A or 0), and on January 13, 1964, the
patient received a chimpanzee xenograft. She was given azathioprine (300
mg/day), actinomycin C (200 mg/day), and prednisone (50 mg/day) before
the surgery. Using general anesthesia, the surgeon removed en bloc both
donor kidneys, ureters, and adjacent segments of aorta and vena cava after
anticoagulation and irrigation. The aorta and vena cava were joined to the
recipient's external iliac artery and vein, respectively, in an end-to-side
anastomosis. The renal ischemia time was about 40 minutes. Postopera-
tively, the patient was maintained on azathioprine (300—400 mg/day),
steroids (50—75 mg/day), plus four doses of aetinomycin C (400 mg) and
X-irradiation (200 rads) to the graft over the week post transplantation
(Tx). Urine output was 7000 ml within 24 hours post surgery. By day 3, the
BUN had fallen from 116 mg/dl before the surgery to 12 mg/dl; the serum
creatinine dropped from 21 mg/dl before the surgery to 0.9 mg/dl; the
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creatinine clearance was 50 ml/min; and the blood pressure was 110/70
mm Hg.
The patient's subsequent course was uneventful. She had normal renal
function until day 23, when her urine output dropped to 1000 ml/24 hr, the
BUN rose to 28 mg/dl, and the creatinine rose to 1.9 mg/dl; the creatinine
clearance was 31 mI/mm, and the urinary sodium was 12 mEq/24 hr. This
episode of acute rejection, accompanied by a slight rise in the titers of
hemagglutinin, was reversed by local irradiation to the graft and increased
immunosuppression. Her renal function returned to normal, although an
unexplained fever persisted for three months. Nine months post trans-
plantation, the patient died after a 24-hour illness of undetermined cause.
At autopsy, anastomoses were intact and xenografts appeared normal.
Histologic examination showed interstitial fibrosis, a low-grade mononu-
clear cell infiltrate, focal glomerulosclerosis, and subintimal proliferation
of medium-sized arteries.
"Patient" 2. In September 1995, as part of a program to develop
xenotransptantation as a practical alternative to allotransplantation in
clinical practice, a group led by David White at the University of
Cambridge, Cambridge, UK, performed a pig-to-Cynomolgus monkey
renal xenograft. The donor was one of a herd of transgenic pigs expressing
the human regulator of complement activation, decay-accelerating factor
(DAF, CD55), which blocks the formation of the C3 convertase. The
recipient was treated with cyclophosphamide and steroids, beginning in
the pre-operative period, and underwent bilateral host nephrectomy,
followed by an orthotopic xenograft. Urine output began immediately and
renal function remained normal throughout the followup period of 30
days.
Discussion
DR. WAYNE W. HANCOCK (Associate Professor of Pathology,
Harvard Medical School, New England Deaconess Hospital, and
Sandoz Center for Immunbiology, Boston, Massachusetts, USA):
These case reports illustrate many of the key features of xeno-
transplantation and will be considered in the context of the past
(case 1) and present (case 2) status of this developing field.
The first case involves the longest human survival ever of an
organ xenograft, 9 months. Initial scientific reports of renal
xenotransplantation, or heterotransplantation as it was known
until the 1970s, were published more than 90 years ago (Table 1)
and were well known to the New Orleans group. Princeteau, in
1905, placed slices of rabbit kidney in the nephrotomy of a child
with renal failure and noted an immediate increase in urine
output and cessation of vomiting, although the patient died of
pulmonary complications on day 16 [3]. In 1906, Jaboulay tried
xenografting with vascular anastomosis of a pig kidney and, in a
second case, a goat kidney, into the antecubital space, but neither
graft functioned, apparently because of vascular thrombosis [4]. In
1910, Unger grafted the kidneys of a non-human primate into a
man with renal failure, but the patient died at 32 hours with
venous thromboses [5]. Neuhof, in 1923, transplanted the kidney
of a lamb into a patient dying of mercury poisoning; the patient
died 9 days later, apparently of nonrenal causes [6].
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Survival
Year Donor No. (time) Investigator Reference
1905 Rabbit
1906 Pig
1906 Goat
1910 Non-human
primates
1923 Lamb
1963—64 Chimpanzee 12
1963—64 Baboon 6
1964 Rhesus 1
monkey
1964 Baboon 1 4.5 days
__________
Mean survival of 36 days.
Scientific interest in this approach subsequently declined as it
became clearer through studies in experimental models that
allografts and xenografts were subject to a powerful immune
response. In the mid-1950s, as immunosuppressive drugs were
first introduced, and as allografting between twins became estab-
lished as a viable means for overcoming renal failure and provid-
ing a good quality of life, interest in transplantation was revived.
However, problems with organ procurement and a limited knowl-
edge of organ preservation severely curtailed the development of
clinical transplant programs. Reemtsma and colleagues began a
program of experimental xenotransplantation using chimpanzees
as donors; these animals had been discarded from circuses or from
the burgeoning space program of the time. A series of 6 patients
received chimpanzee xenografts during 1963 and 1964, and 12
patients overall received a non-human primate graft [1]. All
patients had terminal uremia and were maintained on dialysis.
Each was offered the choice of supportive therapy only, an
allograft (living-related or cadaveric) if and when available, or a
xenograft. The longest survival was that of Patient 1; a second
patient died on day 63 post Tx after developing sepsis.
Other groups also explored xenotransplantation around that
time (Table 1) [7, 81. Of note, Tom Starzl, working at the
University of Colorado, performed six baboon-to-human renal
xenografts (single or dual kidney grafts were undertaken) in late
1963 and early 1964 [7]. Recipients underwent simultaneous
bilateral nephrectomy and splenectomy and were treated postop-
eratively with azathioprine and prednisolone. Baboon grafts func-
tioned somewhat less adequately than did chimpanzee grafts
(mean creatinine clearance of 46 mI/mm at 24 hours post Tx) and
typically lasted a little more than one month. Histologic examina-
tion generally showed a mononuclear cell infiltrate in the early
post-Tx period with associated peritubular capillary damage,
followed by the development of fibrinoid necrosis of larger vessels
with cortical and subcortical infarcts, consistent with the progres-
sive development of humoral rejection, from nine days post Tx.
With the death of all six patients receiving baboon xenogralts, the
program was halted.
Around this time, groups active in the field of xenotransplan-
tation reached a consensus. Compared with the use of baboons or
Rhesus monkeys, they believed the chimpanzee was the best
choice as a non-human primate donor. Even in the 1960s,
however, only minuscule numbers of chimpanzees were available
for this purpose; this situation worsened in later years as the
chimpanzee was recognized as an endangered species. By 1965,
chronic dialysis and cadaveric transplantation became available
and, in the absence of effective means for controlling xenograft
rejection, all groups discontinued their clinical xenograft studies.
Kidney supply versus demand
In the U.S., as indicated in 1994 data from the United Network
for Organ Sharing (UNOS), approximately 3000 patients die
annually awaiting an organ transplant. A further 100,000 die
without having qualified for a place on the respective waiting list,
because of their age or other conditions. Figure 1 illustrates the
severe shortage of human kidneys available for transplantation in
1994. The trend in supply versus demand is bleak. During the
period 1988—1994, the waiting list increased at a rate of 22.4% per
year, while the total number of transplants increased by only 8.1%
per year. Using the 22.4% rate of increase per year, the waiting list
by the year 2000 will be approximately 60,000 patients, the bulk of
whom will be on renal transplant lists. Indeed, UNOS estimates
that fewer than 50% of patients under 50 who are receiving
dialysis are placed on renal transplant waiting lists (27,498 for
1994), in part because their chance of finding a donor is consid-
ered bleak. Given that at least 186,822 patients in the US currently
undergo dialysis, a demand for 100,000 organs for renal transplan-
tation by the year 2000 is likely [1.
choice of a donor species for xenotransplantation
and the risk of zoonoses
Given the vely limited availability of chimpanzees for use in
xenotransplantation, other species have received attention as
potential sources of organs for human xenotransplantation. Ba-
boons are about 30 times more plentiful than chimpanzees, but, as
with use of non-human primates generally, have important logistic
and other limitations. Indeed, none of these species does well in
captivity, all have long gestation times and relatively few offspring,
and their use is expensive and leads to widespread objections on
ethical grounds.
In addition, the U.S. Food and Drug Administration's Biolog-
ical Response Modifiers Advisory Committee (BRMAC), in
hearings completed in July 1995, has evaluated the public health
Table 1. Renal xenotransplantation involving human recipients
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Fig. 1. Breakdown of 1994 UNOS data concerning the numbers of renal
allografts peiformed (11,390), the number of patients on official transplant
unit waiting lists (27,498), and those who died awaiting a transplant (1,376).
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significance of clinical trials involving xenogeneic tissues and
organs [10]. Summaries and recommendations arising from these
hearings will be published in the Federal Register in the near
future. With the background of the HIV epidemic and recent
Ebola virus outbreaks, BRMAC expressed particular concern
over the potential for inadvertent transmission of infectious
agents that would pose a threat to the recipient, health care
workers, their contacts and, potentially, the general community.
The committee concluded that primate donors pose the greatest
risk for transmission of latent or intracellular organisms, including
retroviruses.
Seeking an alternative to primate organ donors, most investi-
gators have settled on pigs as potential xenograft donors. More
than 90 million pigs are raised and slaughtered in the U.S. each
year. In contrast to non-human primates, pigs breed well in
captivity and have large litters. Further, their use raises few
objections in the broad community. The BRMAC felt that the use
of porcine tissues for xenotransplantation was less likely to
introduce new pathogens to humans, given the close and long-
term contact between these species. It is anticipated that the FDA
regulatory guidelines for xenotransplantation will promote the
development of animal sources of donor organs that are free of
zoonotic disease, place responsibility for ensuring the quality of
donor tissues on the supplier, and urge transplant teams to
independently monitor the microbial status of donor tissues and
provide long-term followup of patients and their contacts in order
to monitor the development of diseases of public health signifi-
cance.
The use of pigs as xenograft donors predictably has its prob-
lems, the key one to date being that pig xenografts elicit hyper-
acute rejection when transplanted into primate recipients. Caine
suggested the use of the terms concordant and discordant to
describe the relationship of various species with regard to Xe-
nografting, with the emphasis on the outcome following revascu-
larization [1fl. In concordant combinations, including non-human
primates to humans, rejection typically occurs after several days,
whereas in discordant combinations, such as pig-to-primate, a
violent response and fulminant rejection can occur within minutes
to a few hours after transplantation.
Immunobiology of discordant xenograft rejection
With the sole exception of a pig liver that was transplanted into
a patient with end-stage liver failure [12], and which survived less
than 24 hours, all relevant data have come from pig-to-non-
human-primate transplantation, plus ex-vivo perfusion or cell
culture studies. The key points are as follows. Humans have
preformed, so-called xcnoreactive, natural antibodies (XNA)
reactive against non-primate species [13]. These XNA include
1gM, IgG, and probably IgA classes and appear to arise in early
neonatal life following colonization of the large bowel by coliform
bacteria. The majority of XNA recognize carbohydrate moieties
associated with the bacterial cell wall and are polyreactive,
binding many similar but non-identical residue sequences.
Demonstration of the presence of such XNA in humans, apes,
and Old World monkeys (catarrhines) but not other species,
including New World monkeys (platyrrhincs), provided the key to
our understanding of the outcome of discordant xenografts in-
volving humans or baboon recipients [reviewed in Ref. 14]. The
majority of human XNA are directed against a terminal carbohy-
drate of linear B-type, Galc1 ,3-GaliGlcNAc-R, in which a
galactosyl residue is linked to another galactosyl residue, which in
turn is linked to an N-acetyl-glucosaminyl residue; this process is
controlled by a glucosidase not found in humans, called galactosyl
transferase.
A number of groups are attempting to "knock out" expression
of the al,3 galactosyl transferase gene by porcine cells as a
strategy for markedly diminishing their immunogenicity following
xenotransplantation [reviewed in Ref. 15]. Antisense approaches
have shown that such a step largely abrogates the cytotoxicity of
human serum for pig cells in vitro, and once development of a
suitable pig stem cell line is achieved, targeting of this gene by
homologous recombination is planned. However, in a sobering
series of experiments, d'Apice's group reported that targeted
deletion of the gene in mice did not significantly affect the survival
of mouse xenografts transplanted into non-human primate recip-
ients; preliminary data show the appearance of a terminal N-
acetyl-fucosamine epitope in the knockouts that also is recognized
by human XNA [16]. Because decreasing the immunogenicity of
porcine tissues for primate recipients by manipulation of the
donor animal is currently not practical, various groups have
studied downstream events and considered potential sites for
therapeutic intervention. I will consider the pathobiology of
discordant xenograft rejection next [reviewed in Refs. 17—19], and
will look at current strategies for interrupting various steps of the
primate immune response.
Revascularization of a porcine xenograft to an unmodified
baboon promptly results in the classic morphologic features of
hyperacute rejection: macroscopic engorgement and discoloration
of the organ. Light microscopy reveals interstitial hemorrhages
with platelet microthrombi (Fig. 2). Immunohistologic analysis
shows typically dense deposition of immunoglobulins and comple-
ment components throughout the vascular bed, consistent with
the presence of host XNA directed against carbohydrate moieties
on endothelial and other cells, and activation of complement
through the classical pathway. Early studies emphasized the
predominance of 1gM deposition [201, but recent investigations
have established that IgG and IgA also are deposited [21, 22]. This
latter observation is more than a trivial point, because the
presence of IgA antibodies provides a mechanism for activation of
the alternate pathway of complement, in addition to classical
pathway activation by 1gM and IgG. Further, the alternate
pathway components, including properdin and Factor B, co-
localize with intragraft IgA during hyperacute rejection [221.
Similarly, the presence of IgG can provide a ready means for
recruitment and activation of leukocytes bearing Fc receptors
(CDI6, CD32, CD64) in grafts that survive the initial post-Tx
period.
Platelets. Though far less studied than XNA and complement,
hyperacute rejection also features activation and degranulation of
platelets, potentially as a result of local generation of complement
fragments (C5h-C9); C3a- and C5a-induced mast cell degranula-
tion, histamine and serotonin release, and local generation of
platelet-activating factor (PAF); FcR signaling upon exposure to
deposited XNA; or ischemic injury and cndothelial cell retraction
resulting in platelet GPIh interaction with subendothelial matrix-
bound von Willebrand factor (vWF). That is, even in the absence
of complement activation, multiple signals stimulate platelets. An
additional mechanism might be the very rapid loss of endothelial
ecto-ADPase, which normally maintains a non-thrombogenic
state at the endothelial surface; loss of ecto-ADPase expression
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Fig. 2. Photomicrographs of some of the key features of I-JAR, using an
example of the guinea pig-to-rat cardiac model. A. H&E showing a classic
picture of hyperacute rejection (HAR) with interstitial hemorrhages(RBC) and platelet microthrombi (arrow) within a dilated venule. B.
Dense fibrin deposition along all vascular membranes. C. Pre-transplant
venules lack labeling for P-selectin as shown using an antibody that
recognizes a conformational determinant (arrows indicate endothelial
cells). D. Venules and platelets show stimulation of surface EC expression
of P-selectin by 10 minutes post transplant (arrows). (Panels B-D, immu-
noperoxidase labeling, hematoxylin counterstain, cryostat sections.)
occurs as a result of ischemia/rcperfusion injury, complement
activation, and other factors [23]. Although platelet microthromhi
formation might not be extensive enough to cause rapid graft
dysfunction through purely physical disruption of blood perfusion
through the microvasculature, platelet aggregation and activation
lead to fibrin deposition. In addition, as Twill discuss in a moment,
if hyperacute rejection is avoided, the development of delayed
xenograft rejection can be linked to platelet activation in the very
early post-Tx period. Targeting of platelets with an anti-P-selectin
antibody [24], PAF antagonist [24], or GPIIb/IlIa antagonist [25]
significantly prolongs xenograft survival in some discordant mod-
els.
Coagulation. Rapid assembly of coagulation factors on the
platelet surface results from several related events. Receptors for
factor V are upregulated upon platelet activation, and platelet
membrane phospholipids are exposed as a result of microparticle
formation, facilitating the binding and assembly of a prothrombi-
nase complex. Platelets also degranulate, yielding high local
concentrations of fibrinogen and other coagulation factors present
in alpha granules. Finally, the trigger for platelet aggregation
provided by thrombin or collagen causes a release of ADP and
serotonin. The combined effects of local platelet aggregation and
activation, activation of coagulation and dense fibrin deposition,
cause graft ischemia and rapid, progressive loss of organ function.
A key role for coagulation, as powerful as that of complement,
was recently demonstrated in an ex-vivo perfusion system [131,
and studies to examine the targeting of thrombin in vivo are
underway [26].
Type-I endothelial activation. Knowledge of endothelial re-
sponses during hyperacute rejection is very limited. Considerably
more is known about the effects of XNA, complement, and
thrombin on cultured endothelial cells (EC) [4]. Endothelial
responses during hyperacute rejection do not involve gene acti-
vation or protein synthesis and are therefore examples of what
may be termed EC stimulation or type-I EC activation. Within
minutes of revascularization, P-selectin is translocated from cyto-
plasmic Weibel-Palade bodies to the membrane surface, where it
persists for several hours (longer than predicted by in-vitro studies
wherein P-selectin expression typically lasts only minutes) [24, 271.
P-selectin upregulation in vivo can occur as a result of EC
stimulation by thrombin, histamine, or the membrane attack
complex of complement (C5b-9). Additional events reported
include the loss of membrane ecto-ADPase [23], which contrib-
utes to platelet aggregation, and, based on in-vitro data, C5a-
induced loss of heparan sulfate [28, 29]. Also reported was
exposure of foreign carbohydrates such as sulfatides [30]. Both of
these events can activate the contact system of coagulation.
Summaiy of hyperacute rejection. Immediately upon revascular-
ization of a discordant xenograft, complement activation begins
on the surface of endothelial cells. The anaphylatoxins C3a and
C5a are generated and act locally on basophils and mast cells to
release histamine and cause degranulation of platelets, including
serotonin. Within seconds, histamine and serotonin bind to
receptors on endothelial cells, stimulate surface expression of
PAF and P-selectin, and cause cell contraction. Platelet-activating
factor dramatically increases vascular permeability and endothe-
hal cell contraction, which result in sludging of platelets and red
blood cells within the microcirculation. Endothelial cell retraction
exposes underlying vWF, basement membranes, and collagen-to-
plasma components, including platelets and the contact activator,
Hageman factor. Together, these responses result in stasis, plate-
let aggregation, and interstitial hemorrhages, all of which rapidly
reduce contractility and cause the vascularized xenograft to fail
within minutes of engraftment.
Overcoming hyperacute rejection of discordant xenografts
Given the complex and manifold involvement of antibody,
complement, coagulation, and other inflammatory pathways in
the mediation of xenograft rejection, identification of the key
events that arc therapeutically significant is essential. The current
distillation of much data is that complement is the key target.
Thus, although XNA depletion—through various combinations of
splenectomy, plasmapheresis, absorption with soluble trisacchar-
ides, organ perfusion, and immunosuppression— has shown the
important role of antibody in the development of hyperacute
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rejection in the pig-to-primate combination, regardless of the
protocol, antibody targeting has been incomplete, difficult to
maintain, and at best has prolonged the xenograft in a few isolated
cases from several hours to 14 or 15 days. Similarly, the effects of
targeting the coagulation system alone, or inflammatory media-
tors such as PAF, often result in statistically significant effects
compared to controls (for example, up to a few hours prolonga-
tion of graft survival), but these effects are not biologically
meaningful.
Targeting of the complement pathway by decomplementation
with cobra venom factor or one of several alternate (but less
effective) agents, such as soluble complement receptor type 1
(sCR1) [311 or FUT-175 or K76COOH [22], is about equally
effective as targeting of XNA, providing several days of graft
survival. However, with the realization that the arcane world of
complement includes multiple regulators of complement activa-
tion (RCAs) and that such RCAs are species specific [reviewed in
Ref. 32], genetic approaches to manipulation of the organ donor
became feasible in ways other than deletional targeting of pig
galactosyl transferase. The main human RCAs are CD46 (mem-
brane cofactor protein) and CD55 (decay accelerating factor),
which regulate expression of C3 convertase, and CD59 (homolo-
gous restriction factor), which blocks the insertion of C9 into the
developing membrane-attack complex of complement. The prin-
ciple of this approach has been demonstrated in vitro, wherein
transfected pig cells show dramatically increased resistance to
complement-mediated lysis in the presence of human serum [33].
However, the key goal has been the development of transgenic
pigs expressing human RCA and the testing of this approach in
vivo.
Just prior to Christmas of 1992, Astrid, the world's first
transgenic pig, was born. Astrid was heterozygous for human
CD55 and became the founder pig of a large herd at Cambridge
University. In initial studies, this transgenic approach has proven
successful in vivo, since in contrast to normal controls, which
reject within minutes to a few hours, organs (heart or kidney)
from pigs heterozygous for human RCAs such as CD55, when
transplanted into unmodified baboon recipients, survive about 5
days (120 hours); grafts from homozygous donors survive approx-
imately 130 hours [2]. Hence, expression of human RCA on pig
endothelial cells can abrogate hyperacute rejection following
xenotransplantation. Initially, pigs transgenic for CD55 had un-
predictable and often low tissue expression, but the application of
new vectors now allows adequate expression of this transgene in
porcine endothelium. In particular, the use of mini-genes that
include at least one intron and the expression of which is driven by
the human CD55 promoter has proven very successful. We will
now consider the beneficial effects of adding immunosuppression
on xenograft survival in recipients of transgenic pig organs (as in
"Patient" 2).
Immunopathology of delayed xenograft rejection
If hyperacture rejection is avoided by depleting XNA or by
blocking the action of complement, xenografts are rejected in
days, instead of minutes to hours, by a process referred to as
delayed xenograft rejection (DXR) [27]. DXR (Fig. 3) is a rather
uninformative moniker, especially when compared to standard
terms such as hyperacute, acute, or chronic rejection, which have
clear morphologic features, and for which, at least in the case of
the two former conditions, a considerable amount is known
Type II EC activation
Leukocyte adhesion, procoagulant and cytokine production
Fig. 3. Diagram of DXR, with emphasis on disruption of pathways that
regulate the normal anticoagulant state as well as mononuclear cell infiltra-
tion and cytokine production and endothelial cell (EC) activation. During
DXR, endothelial cells lose their normal ADPase, AT-Ill, and thrombo-
modulin (TM) expression, shifting to a net procoagulant state. This is also
facilitated by the activation of host macrophages to express tissue factor,
and their production of many cytokines that affect organ function as well
as promote endothelial activation and injury, with many interactions and
amplification loops contributing to stasis, graft hypoxia, and eventual
organ failure.
regarding the contribution of humoral and cellular immune
responses to their development. By contrast, large vessels in DXR
are typically uninvolved. Thus DXR's description as vascular
rejection by some is a misnomer, and labeling the process as
cellular rejection conjures up T-cells, whereas such cells aren't
necessary for DXR to occur [34]. Hence, DXR merely indicates
the typical timing of rejection in experimental recipients who are,
in effect, de-complemented, whether through cobra venom factor
or an analogous agent, or through the donors' expressing RCA
but who are otherwise unmodified. It is important to remember
that hyperacute rejection and DXR represent parts of a contin-
uum. Some of the components of hyperacute rejection, such as
platelet activation or immunoglobulin deposition, do not typically
result in hyperacute rejection if complement activation is avoided.
Yet these responses, as well as activation of coagulation and
endothelial cell responses, can contribute to DXR.
Delayed xenograft rejection occurs in large [35] and small
animal [271 models of discordant xenograft rejection, and is
characterized by progressive infiltration over several days of
mononuclear cells, primarily monocytes and natural killer (NK)
cells, the development of focal infarcts and interstitial hemor-
rhages, widespread activation of coagulation within the microvas-
culature, and cessation of graft function. Such a clinicopathologic
picture is not simply a delayed form of vascular rejection. The
observation that the same events occur in 1gM-depleted recipients
[34] means that other pathophysiologic processes are involved.
Platelets. Platelet exposure to PAF, thrombin, or complement
fragments stimulates membrane expression of P-selectin. If xeno-
grafts are not subject to hyperacute rejection, surface P-selectin
provides a tethering point for adhesion of leukocytes, especially
monocytes. In addition, platelets contain chemokines that arc
expressed upon activation; a key example is RANTES [35, 36].
Thus, local platelet aggregation and activation result in release of
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Fig. 4. Immunohistology of DXR. Pathognomonic features are A dense
macrophage infiltration, with B TNF-a production, as well as C NK cells
producing D IFN-y, in the absence of E C3. Grafts also show progressive
endothelial cell activation, including F upregulation of E-selectin at 4
hours and G dense tissue factor expression and H fibrin deposition by 24
hours. (Cryostat sections, hematoxylin counterstain, immunoperoxidase,
X 400 magnification.)
potent chemotactic signals that attract monocytes. Monocytes
responding to such signals adhere to newly expressed P-selectin
on platelets and endothelial cells and undergo activation. For
example, P-selectin ligation on the monocyte membrane causes
tissue factor induction [37] as well as production of further
chemokines, including RANTES and MCP-1.
Leukocytes. More than 75% of intragraft leukocytes are mono-
nuclear phagocytes, with additional contributions from NK cells
(1O%—20%) and only very small numbers (—5%) of T-cells (that
is, those bearing classical TCR-cs/j3) until at least several days post
Tx. The presence of T-cells or XNA is not essential for DXR in
complement-depleted rats [34], but it has been difficult to deter-
mine the actual roles of macrophages and NK cells.
Infiltrating macrophages produce large amounts of TNF-a and
1L-1 during xenograft rejection, as well as IL-7, IL-12, iNOS, and
various chemokines (Fig. 4). Some monokines, such as TL-13 and
lL-6, are likely to act only on host cells, for example, contributing
to systemic fever and acute phase response. Others, like TNF-a,
appear to act across species, and the upregulation of adhesion
molecules is consistent with such effects. TNF-a also has direct,
toxic effects on myocardial cells. Both IL-7 and IL-12 arc relevant
to NK cell recruitment and activation, with IL-12 playing a key
role in the induction of IFN-y production. Xenografts display
extraordinarily dense IFN-y expression during DXR. The extent
to which TFN-y acts across species is controversial, however, and
appears to depend on the species combinations involved. Never-
theless, because IFN-y is the most potent activator of macro-
phages known (regardless of direct effects across species barriers),
the action of IFN-y on host macrophages is likely to he dramatic.
Although macrophages are notoriously difficult to deplete, the
opposite experiment involving the transfer of macrophages from a
complement-depleted rat recipient of a guinea pig xenograft to a
naïve complement-depleted recipient accelerates DXR; thus a
role for macrophages in the pathogenesis of DXR is likely [38].
There are no data as yet concerning the results of NK cell
depletion in discordant models.
FcR -dependent leukocyte recruitment. Several mechanisms could
explain the recruitment of macrophages and NK cells, which
occurs from an early stage following engraftment in complement-
depleted recipients; these mechanisms include immune adherence
via FcRs, lectin binding, and the actions of chemokines. Both
leukocyte populations express FcR (CD16/FcyRIII, CD32/CD16!
Fc-yRII), and macrophages also express CD64 (CD16!FcyRI).
Such FcRs are important to the development of antibody-depen-
dent cell cytotoxicity, cell activation, and phagocytosis. However,
binding via FcR might not be critical, as depletion of IgG-XNA to
<5% of normal rat serum through plasmapheresis and B-cell-
directed immunosuppression does not affect cellular infiltration or
the temporal course of DXR [34].
Lectin expression. Macrophages and NK cells express lectins
that recognize a variety of carbohydrate residues. No data are
available as to the in-vivo significance of recently identified NK
cell lectins [39], although intragraft rat NK cells do express the
NKR-P1 lectin [27]. In some animal models of tumor immunity
and chronic allograft rejection, induction of macrophage lectin
expression can provide a novel means for macrophage recruit-
ment, activation, and development of cell cytotoxicity. We have
investigated macrophage lectin involvement in DXR by synthe-
sizing peptide sequences based on the recently cloned rat C-type
macrophage lectin and preparing mouse anti-rat hybridomas [40].
Comparison of serial guinea pig-to-rat xenografts with rat cardiac
allografts showed selective and dense expression by infiltrating
macrophages within xenografts; labeling was present by 12 hours
and peaked at 4 to 5 days with complete destruction of xenografts;
corresponding allografts lacked more than trace macrophage
lectin labeling. Moreover, induction of macrophage lectin on
activated rats' macrophages was comparable in nude or XNA-
depleted xenograft recipients, and upon incubation of rat macro-
phages with guinea pig cells in vitro. These studies show that (1)
rat macrophages undergo activation when exposed to xenogeneic
cells, (2) macrophage lectin expression is a key early feature of
DXR, even in the absence of host T-cells or XNA, and thus (3)
targeting of macrophage lectin with specific monoclonal antibod-
ies or administration of specific sugars to saturate the membrane
molecule may be a new approach to blocking macrophage infil-
tration and activation during DXR.
Chemokines and leukocyte recruitment. A third and perhaps key
means for mononuclear cell recruitment is the intragraft expres-
sion of chemokines. Analysis of pig hearts grafted into baboons in
which hyperacute rejection was prevented using cobra venom
factor allowed serial studies of DXR in higher animals [35].
Macrophages began to accumulate around P-selectin-positive
(activated) platelets by 4 hours; this finding is important for
identifying potential targets. These platelets expressed RANTES,
which was detectable within minutes of platelet activation in the
early post-Tx period. By 4 hours, additional C-C chemokines such
as MCP-1, MCP-2, and MIP1b were present in considerable
amounts. Given that the latter cytokines recruit and activate
macrophages and NK cells [36], and that grafts by day 5 showed a
dense accumulation of activated macrophages and lesser numbers
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of NK cells, no single chemokine is likely to be responsible for
mononuclear cell entry into rejecting xenografts. Whether intra-
graft chemokine expression can be blocked or diminished by
targeting very early events remains to be tested. Rodent models
have illustrated that the use of a GPHb/IIIa antagonist to block
platelet activation significantly improves graft survival, at least in
part by decreasing intragraft mononuclear cell recruitment [251,
but as intragraft inflammation develops, a multitude of cell types
can produce these chemokines, thereby rendering successful
targeting unlikely when using this strategy alone.
Endothelial responses. Analysis of serial samples from small [27]
and large animal models [351 has demonstrated considerable
evidence of endothelial cell activation during discordant xenograft
rejection. Endothelial responses include the following: (1) a shift
to a procoagulant state, with downregulation of surface thrombo-
modulin and induction of tissue factor, consistent with dense local
fibrin deposition; (2) induction of leukocyte adhesion molecules,
including, progressively, E-selectin and ICAM-1; and (3) produc-
tion of chemokines such as MCP-l as well as other cytokines.
The significance of endothelial activation in DXR is controver-
sial. On the one hand, these "downstream" events are present in
essentially any inflammatory response, albeit to a more florid
extent than usual. On the other hand, the ability to genetically
engineer the donor animal suggests the potential for modulating
endothelial responses by genetic approaches, for example, by
regulated targeting of NFKB-dependent endothelial cell pathways
[17, 18]. Our research group holds, as a unifying concept, that in
lieu of dense T-cell-directed immunosuppression, with additional
targeting of complement, coagulation, and host macrophage and
NK cells, modulation at the graft level by such genetic approaches
will be important to the development of clinical xenotransplanta-
tion as a practical solution to the lack of organ donors; testing in
vivo in small animals is underway.
Summary. Our data indicate that after hyperacute rejection is
overcome by cobra venom factor treatment, xenografts undergo a
series of steps involving mononuclear and endothelial cell activa-
tion, cytokine expression, platelet and fibrin deposition, and
rejection within a few days. Logically, DXR can be caused by (1)
infiltrating mononuclear cells; (2) consequences of EC activation;
or (3) a combination of (1) and (2). Natural killer cells could be
present secondary to direct "recognition" of xenogeneic EC, and
either cell type could be present through FcR binding of IgG
bound to EC, lectin interactions, or chemokine production.
Aspects of direct binding and activation of endothelial cells by
macrophages and NK cells recently have been described [41, 421.
Once present and activated, mononuclear cell products, including
cytokines and tissue factor, contribute to coagulation, damage
surrounding endothelial cells, and depress myocardial contractil-
ity. The factors that result in activation of endothelium in DXR
are not well defined. Xenoreactive natural antibody binding to pig
EC in vitro upregulates IL-I, IL-8, and PAl-i [17], although the
in-vivo relevance of this finding is not known, Following stimula-
tion, activated endothelial cells contribute to inflammation and
thrombosis.
The most likely explanation in my opinion is that DXR is based
on a combination of the effects mediated by activated mononu-
clear and endothelial cells, in this schema, any one event that
leads to activation of either the donor organ endothelium or host
mononuclear cells would likely become amplified via the multiple
interactive circuits between inflammation and coagulation. As NK
cells are stimulated, they release IFN-y, which promotes macro-
phage activation, cytokine production, and other responses. Re-
lease of TNF-s from activated mononuclear cells could activate
endothelial cells, causing a further recruitment of leukocytes
through induction of adhesion molecules, as well as stimulation of
a procoagulant state through upregulation of tissue factor and
downregulation of thrombomodulin and antithrombin-III. Down-
regulation of thrombomodulin expression, resulting in a markedly
reduced capacity of EC to bind thrombin and activate protein C,
might further increase macrophage cytokine production, since
activated protein C appears to have a key role in inhibition of
macrophage activation in vivo and in vitro [43, 44]. Delayed
xenograft rejection might be caused by the cumulative effect of
fibrin generation and local hypoxia; the toxic effects of TNF, IL-I,
and other cytokines; or a direct effect of mononuclear cell binding
to EC. The extent to which T-cell activation contributes to this
process, if DXR is prolonged further, remains to be determined.
The future of xenotransplantation
Today's second case, the pig-to-primate combination, illustrates
the state of the art in experimental discordant xenotransplanta-
tion. The addition of cyclophosphamide and steroids induced a
leukopenia and markedly lowered the circulating platelet count.
This regimen markedly enhanced survival—up to 63 days in a
cardiac xenograft recipient, and up to 30 days in a renal xenograft
recipient ("Patient" 2) before ill health of the animals required
that they be sacrificed. Recipients typically suffered from diarrhea
and weight loss associated with gastrointestinal toxicity and infec-
tions (?mixed CMV and candidial esophagitis, duodenitis) as a
consequence of the immunosuppression. Biopsies of xenografts
showed normal histology, including a lack of any leukocyte
infiltrate, platelet thrombi, or interstitial hemorrhages, and the
animals had normal renal function. Based on these initial results
with transgenic pigs expressing human RCA, it appears that
hyperacute rejection can be overcome. This outcome is the first
major triumph of gene therapy in the field of organ transplanta-
tion. However additional, non-clinically acceptable immunosup-
pression is required to overcome DXR and, presumably, T-cell-
mediated xenograft rejection. The challenge for us is to develop a
protocol using such pigs that will allow long-term survival without
compromising the host.
Alternately, further genetic manipulation of the donor appears
a likely area for progress, with the eventual strategy of crossing
pigs expressing human RCA with those expressing other genes or
those in which certain genes have been silenced. Likely candidates
arc listed in Table 2. These include overexpression of an H-
transferase to decrease gal(al,3)gal expression; regulated expres-
sion of an inhibitor of endothelial cell activation, for example,
through overcxpression of an inhibitor of NFKB; and eventually
possible development of "self-pigs" bearing human major histo-
compatibility complex genes of the recipient, potentially in con-
junction with knockout of swine MHC class-I antigens. Progress
on some form of galactosyl transferase knockout in pigs also is
likely within the next two years.
On a final note, it is worth remembering that the field is faced
with almost evangelical fervor from proponents of xenotransplan-
tation advocating immediate clinical trials with organs from the
currently available transgenic pigs. We arc acutely aware of the
crisis in organ donation rates versus numbers of patients waiting
for organs, so it is important to ponder for a second the things we
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Table 2. Genetic manipulations of the pig organ donor to promote xenotransplantation
Target Concept
--__Comment Time frame
Transgenic Expression of human CD46, CD55 or Prevents hyperacute rejection but without Testing
expression of CD59 on pig cells will locally additional immunosuppression, xenografts underway
human RCA regulate assembly of complement
cascade
reject in —5 days; alternate vectors to
increase endothelial expression are being
evaluated (e.g., CD55)
Transgenic al,2 Fucosyltransferase overexpression May usefully be combined with pigs transgenic 1—2 years
expression of H- may compete with endogenous al,3 for RCA
transferase galactosyl transferase
Transgenic Regulated expression of 1KB, a natural Strategy to inhibit NFKB, a key transcription 1—2 years
expression of inhibitor of NFKB, or a dominant factor essential for inducible gene expression
inhibitors of negative mutant of the NFKB subunit in endothelial cells; regulation of inhibitor in
endothelial ReIA, by endothelial cells vivo achieved through use of tetracycline-
activation sensitive promoter
Yeast artificial Large portions (—150—300 kb) of May be used to achieve position-independent 2—3 years
chromosome human chromosome carrying desired expression of multiple human genes; in long(YAC) transfer of transgene term could be used to introduce human
human genes MHC genes into donor pig, creating "self-
pig'
al,3 Galactosyl Block pig expression of Galal,3Gal Requires isolation of a pig stem cell line; other 1—2 years
transferase residues recognized by human XNA sugars may still bind XNA
deletion
Swine MHC (SLA) Block pig expression of pig MHC genes Requires isolation of a pig stem cell line; pig 2—3 years
deletion to facilitate tolerance induction 132-microglobulin cloned so targeting of
swine class I feasible; class Ii genes have
very restricted expression and may be less
important
don't yet know. None of the trials of very small numbers of
pig-to-primate xenografts has yet addressed issues of biocompat-
ibility. No data on the basic physiology of porcine renal function
following xenografting are yet known, nor are more subtle factors
understood, such as erythropoietin production, the graft's ability
to grow in the host, hemodynamic factors and, as occurred even
with a chimpanzee donor, the potential for rapid development of
chronic rejection. The coming two years are likely to see far more
attention paid to such issues, as well as the establishment of
pathogen-free colonies, before clinical trials are seriously consid-
ered worthwhile.
Questions and answers
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston, Massachusetts): Is there any way of using bone
marrow transplants as a halfway house before carrying out
transplantation of the organ that you'd like to study, the kidney?
DR. HANCOCK: Bone marrow transplantation as a way of
potentially inducing tolerance to a subsequent organ transplant,
possibly through development of mixed chimerism, is of interest
to many in the field of xenotransplantation, and may, of course, be
an end in itself, as in the recent case of Suzanne Ildstadt's efforts
to use a baboon bone marrow transplant to reconstitute the
marrow of a patient with AIDS [451. Induction of tolerance to
xenografts is of great interest to people such as David Sachs at the
Massachusetts General Hospital, but as I understand, in the
pig-to-baboon model, the best they been able to achieve is about
14 days of survival using a rather complex protocol involving
irradiation and various forms of immunosuppression [46]. They
find histologic events consistent with what we call delayed xeno-
graft rejection, but with a greater emphasis on activation of
coagulation and fibrin deposition and somewhat less mononuclear
cell infiltration, possibly as a result of leukopenia induced by the
conditioning regimen. So, my assessment is that strategies to
induce classical tolerance will in some form eventually have a role
in promoting long-term survival, but that classical tolerance won't
get us past the initial hurdles of hyperacute or delayed xenograft
rejection. Unless profound leukopenia and thrombocytopenia are
induced and maintained, which is not a practical clinical approach,
vascularized xenografts, which have survived the initial 24 hours of
onslaught of antibody and complement, are still rejected within
the next week or two, even without T-cell involvement. This is the
barrier we must overcome—probably only to find further obsta-
cles, such as the T-cell response.
DR. HARRINGTON: Why doesn't the recipient's CD55 turn off C3
convertase even if the pig's CD55 has been turned off?
DR. HaacocK: Many of these regulatory systems act only at the
local membrane as well as being species-specific. We don't know
why they don't work across species. In pig endothelial cells in
culture that have the equivalent of pig DAF or other RCA
molecules on their membrane, if you add human antibody and/or
complement, cell injury and lysis occur; that is, pig RCAs don't
stop assembly and formation of human C3 convertase and termi-
nal membrane complex. By contrast, if you put in a source of
human soluble DAF, for example, to express high levels of DAF,
you block that event completely. There probably are many more
molecular incompatibilities that normally would contribute to
regulation of the immune response in the allograft state, but
which in the xenograft state are unregulated.
DR. NlcoLAos E, MADIAS (chief Division of Nephrolo, New
England Medical Center, Boston): Does the targeted deletion of the
al,3 galactosyl transferase gene in mice affect the binding of human
xenoactive natural antibodies to tissues and activation of comple-
ment'? Do these knockout mice have any structural defects?
DR. HANCOCK: Regarding the knockout mice, the work was
done by another Australian, Tony d'Apice from Melbourne, His
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work was just published and shows that GAL transferase knock-
out mice weren't protected against the effects of human antibody
and complement [47]. When the hearts of the knockout mice were
perfused ex vivo, the mice still showed antibody binding and
complement activation on their endothelial cells. d'Apice suggests
that there are carbohydrate molecules apart from gal(al,3)gal
that are recognized by human XNA.
DR. MAjIAs: Is there a recognized role for these xenoreactive
natural antibodies? Is repeated immunoabsorption of these anti-
bodies in combination with downstream steps a reasonable ap-
proach for facilitating engraftment?
DR. HANCOCK: There's no insight or any knowledge of disease
association of these natural antibodies that I know of. Wonderful
studies by Un Galili over the last decade have shown that these
xenoreactive antibodies make up 1% to 2% of circulating 1gM and
IgG; that is, an incredible portion of our humoral response is
directed towards targeting certain carbohydrates [48]. However,
we don't have any knowledge about their involvement in immune
diseases.
The immunoabsorption stoly is as follows. You can have the
galactosyl residues coupled to a column and establish extracorpo-
real perfusion, or you can treat the recipient with soluble sugars,
in an attempt to mop up the antibody. Sometimes in experimental
protocols, investigators try plasmapheresis, plus or minus B-cell
immunosuppression, including cyclophosphamide. Most of these
cases are accompanied by a marked rebound synthesis of the
antibody, and such approaches haven't achieved anything more
than a day or two's grace in the absence of the antibody. Perhaps
a relevant concept to mention here comes from the work of Fritz
Bach, concerning accommodation [49]. If the accommodation
studies in rodents and a very small number of primates are true,
one could deplete antibody and/or complement and allow them to
return at a gradual rate, such that the graft endothelial cells will
somehow become protected against that otherwise toxic response.
We don't know at this stage how long we have to maintain that
depletion of antibodies. We don't know the optimal protocols for
that. We don't know whether immunosuppression would interfere
with that process. However, like tolerance, accommodation is a
Holy Grail to a number of workers in the xenotransplantation
field.
DR. AJAY K. SINGH (Division of Nephrology, New England
Medical Center): My question addresses the relative importance of
NK and mononuclear cells in the host response to a xenograft.
Among several methods of addressing this issue, cell depletion
studies and cell transfer experiments would he at the top of my
list. Would you elaborate on whether these studies have been
performed and the insights they've provided'?
D. HANCOCK: These sorts of studies are not easy to do in the
pig-primate combination. They have been done, in a few cases, in
rodent models, For example, xenografts into beige mice, which
lack NK cell function, show a very mildly increased survival rate
[50]. There are so many effective mechanisms at play that
targeting any one of them, whether antibody, complement, NK, or
other cells, doesn't result in any biologically meaningful prolon-
gation of survival. However, Fryer Ct al in Minneapolis have
shown that if one transfers monocytes or macrophages from an
animal that has had a xenograft to a naïve animal receiving a
xenograft, the xenograft survival is shortened [38]. In essence,
monocytes/macrophages do rev up the rejection response, hut,
typically, taking out any one single component of this multifacto-
rial response has little effect.
DR. SINGH: One of the "hot-button" issues with regard to
xenotransplantation is the issue of cross-species transmission of
various viruses—in particular, Creutzfeldt-Jacob disease, Ebola,
and HIV—from genetically altered pigs to humans. To what
extent is this a concern? Would you elaborate on the conclusions
of recent working groups on the issue, for example, the Nuffield
report in the U.K.?
DR. HANCOCK: I suspect in the future there will be Nephrology
Forums just on each of the topics you mentioned! The U.S.'
Institute of Medicine and Great Britain's Nuffield Council on
Bioethics recently presented reports on the current status of
xenotransplantation [51]. Last summer, the U.S. government
regulatory panels held hearings on the risk of disease transmis-
sion. Although the results of these hearings haven't been pub-
lished, some of the committee members have noted in quarterly
newsletters much of what was discussed at the hearings. The
committee is thought likely to recommend stringent conditions
regarding the use of primate donors, for fear of disease transmis-
sion. In the case of pig donors, it's not so clear as yet. It's claimed
that, because pigs have been around humans for so many centu-
ries, with established animal husbandry techniques, the risk of
disease transmission is less. How that belief will contribute to the
regulation of institutions or environments where pigs are bred for
xenotransplantation has not been established yet. Clearly, you
want to have purpose-bred pigs. How this breeding would be
regulated, what sort of responsibility the people who raise the
animals will take, and what sort of certification (in terms of
absence of pathogens) will be required is not clear, nor are the
means by which long-term followup of xenograft recipients and
their close contacts is ensured.
DR. ANDREW J. KING (Division of Nephrology, New England
Medical Center): I have two questions. What about phenomenol-
ogy? Will these patients want to eat from a trough?
My second question relates to the rapid response of adhesion of
platelets to the endothelium. Have there been any attempts to
impair this interaction, either with anti-GPIIb/IIIa antibodies or
some other form of depletion, to give us an idea of how important
this interaction is to initiating early acute rejection?
DR. HANCOCK: Your first question is actually more than a jest to
many people. Such issues reflect age-old fears relating back to the
earliest times, and we might speculate on how use of the term
xenophobia might one day extend to those who wish to avoid a
xenograft on the basis of such irrational but deep-seated beliefs.
In the same way that hunters thought that eating certain parts of
the slaughtered prey might increase their hunting prowess or
other powers, we need to recognize that for some individuals,
receiving a particular pig organ will make them feel in some way
like that animal. Think of the adage in our current weight-
conscious world, that "you are what you eat." We are touching on
real fears that will have to he discussed and resolved if xenotrans-
plantation is to be widely accepted. Surprisingly, in the increas-
ingly secular Western world, such issues might be as important to
consider as the more commonly considered religious proscriptions
on the use of the pig, rules part of both Judaism and Islam.
Coming to your second question, Simon Robson, a British
hematologist working with us, is currently leading studies to
dissect the interactions of platelets and endothelial cells following
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transplantation. Our first paper on this issue, published in Trans-
plantation [52], shows that the addition of GPIIb/IIIa antagonist
to a decomplementing protocol using cobra venom factor pro-
longs xenograft survival and improves function, although the
grafts do reject only a day or two later than do cobra-venom-
factor-treated controls. Again, such studies show the potential to
enhance xenograft function by targeting other pathways than just
antibody to complement, but these investigations also emphasize
that delayed xenograft rejection is a multi-factorial problem, such
that targeting of a single additional pathway does not ensure
long-term survival.
DR. KING: You said that P-selectin appears very rapidly on the
surface of endothelial cells. That response time—minutes—is
similar to that for thrombin. What do you think induces this
response in the pigs?
DR. HcocK: As I mentioned from the start, with the trans-
genie pigs expressing DAF or other RCA, what you're basically
doing is stopping assembly of the complement cascade on endo-
thelial cells. You're not blocking xenoactive antibody binding.
Binding of XNA to pig endothelial cells causes P-selectin trans-
location to the membrane and expression. Thrombin produces the
same response, as might local basophil or mast cell degranulation
with local histamine release.
DR. BETH BOUTHOT (Renal Fellow, Division of Nephrology, New
England Medical Center): Is there ABO incompatibility between
pigs and humans? If so, how would that be dealt with?
DR. HANCOCK: Some people ask me about chimpanzees. There
are only two blood groups. The famous patient (Patient 1)
surviving nine months with a chimpanzee xenograft was blood-
group matched. I don't know about pigs; my understanding is that
they don't have comparable blood groups that are relevant to their
status as xenograft donors, excluding the galactosyl transferase
product.
DR. MARK WILLIAMS (Division of Nephrology, New England
Deaconess Hospital): So much of the focus has been on endothe-
hum and activation of antibody responses. In a general sense,
once you get beyond that into primarily cellular immunity, is this
likewise going to be such a barrier?
DR. HANCOCK: Expectations in the field are that the immuno-
suppressives that we have now for allotransplantation will be able
to squash the T-cell cellular response to the xenograft. This is a
reasonable but as yet unproven view. Some experimental evidence
suggests that the indirect pathway of recognition might be a major
issue for xenoreactivity, potentially even greater than that which
we recognize for allorejcction. That may be a problem.
DR. BRIAN J,G. PLREIRA (Division of Nephrology, New England
Medical Center): Could you trace for us the deletion of gal and
other carbohydrate residues from cell surfaces as evolution oc-
curred? Can this change be explained?
DR. l-lANcocK: Un Galili has written on this topic [53]. Essen-
tially, in terms of genotyping primates, lower primates have the
gene that is expressed, whereas upper primates and humans don't
have it. It is thought that it might have been of some evolutionary
advantage for us to not express this gene, perhaps by affording
protection against some infectious agent or parasite, hut precisely
how and why are not known.
DR. PEREII: I'd like to revisit the issue of self-pigs. Self-pigs
would not be feasible in heart or liver transplantation, because
these are emergency transplants leaving no time to breed the pigs.
Why would there be an ethical objection to the development of
self-pigs in renal transplants? Once a patient develops renal
failure, a pig could be bred with the MHC specificity of the given
patient. I believe that this would be no different from the ethical
objection to xenotransplantation in general.
DR. HANCOCK: It may be that engineering of self-pigs would
take the objections to xenotransplantation to another dimension.
Some people will argue that we are trying to take over another
species and exploit them to an unacceptable extent. One of many
other problems, of course, would be the economic consideration.
It's not clear what the health insurance and reimbursement
sequelae might be. Would self-pigs only be an option for the
wealthy elite? Might kidnappers hold your self-pigs for ransom?
Many hypothetical questions regarding their use suggest fascinat-
ing issues for scientists, the public, even novelists!
DR. PEREIRA: In models of sepsis, blockage of one pathway
doesn't necessarily protect one from bypass pathways. If you were
to identify one or two of the most important pathways that need
to be blocked immediately after xenotransplantation and hope
that the host tolerance will develop for the bypass pathways in the
interim, which two would you pick?
DR. HANCOCK: Two is a very small number under these
circumstances; we certainly need to block complement to obtain
any survival at all, and we should block coagulation. It's not clear
how best to promote an anticoagulant state locally. If you asked
for more than two pathways, I'd suggest that we block leclin
interactions as well, because human NK cells and monocytes stick
directly to xenogeneic cells, become activated, and then kill that
cell.
DR. PEREIRA: Why not inhibit NFKB?
DR. HANCOCK: We and others are working on this area inten-
sively right now. Hans Winkler in our center is leading the
development of genetic approaches to blocking NFKB It
might be counterproductive if we start inhibiting these responses
in all cells or all the time.
You asked about infections. It might be, for example, that if we
completely inhibit the NFKB pathway in the endothelium, leuko-
cytes would not be able to enter, adhere, migrate across, and
protect the host against an infectious agent. Hence, we plan to
develop and test transgenic animals in which endothelial-specific
expression of an NFKB inhibitor can be regulated, for example,
using the tetracycline-regulated expression system developed by
Hermann Bujard [551.
DR. SINGH: Would you comment on the potential impact on
xenotransplantation of physiologic differences between pigs and
humans?
D1. HANCOCK: People interested in xenotransplantation and its
immunobiology and experimental aspects are split into at least
two camps as regards clinical application. There are those who
want to be able to transplant an organ from a pig to a primate,
including humans, as soon a possible, given the critical lack of
organ donors. The other camp emphasizes the limitations of our
knowledge, the expense of such trials and investigations, and the
extremely limited data to date regarding hiocompatihility as well
as organ survival and function, not to mention the potential for
disastrous clinical outcomes. The advantage of further testing in
the rodent models is that one can perform a large number of
transplant procedures and mechanistic studies using molecular
biology techniques to increase regulation or expression of the
gene. The criticism of the rodent models is that they might not be
clinically relevant to humans. However, the histologic and biologic
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features of xenograft rejection are very similar with respect to
hyperacute and delayed xenograft rejection both in large and
small animal models, although the mechanism of complement
activation can vary. In addition, such studies in large or small
animal models need to explore issues of biocompatibility before
any clinical trials are even begun to be considered.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): The field of transplantation is replete with
empiric trials of poorly understood therapies. Given the large
number of people waiting for transplants, do you think clinical
trials of xenotransplantation will begin soon?
DR. HANCOCK: Again, there is considerable pressure to move
forward clinically, in the same way that Susan Ilstadt was keen to
try the baboon bone marrow transplant in the HIV patient in
California. One problem with xenotransplantation is that it in-
volves, especially in large animal models, very expensive research,
which is commonly tied in with large biotechnical or pharmaceu-
tical companies. Those companies would like to know that their
area of research, whether development of a transgenic pig or
blocking of a deleterious process, will be effective and result in a
commercial return. On the one hand, they want to know from
trials that xenotransplantation is effective; on the other hand, they
don't want to initiate trials before they have some inkling of the
likely result. It's a delicate balance: legal and patent issues are
commonplace, and optimal strategies may require the use of pigs
developed or engineered by more than one company. For these
and other fundamental reasons, including issues of safety and
biocompatibility, I don't think that significant and sustained
clinical trials will be undertaken for at least several years.
DR. MADIAS: I would like to return to the events of endothelial
activation in delayed xenograft rejection. What do we know about
the subcellular and molecular mechanisms of endothelial barrier
dysfunction, especially as it relates to cytoskeletal protein involve-
ment? What controls the release of endothelial-cell-associated
heparan sulfate?
DR. HANCOCK: I don't know much about the endothelial
retraction in terms of the cytoskeletal actin and filamental rear-
rangements. Little work has been done in that area, at least as it
pertains to xenogeneic insults to the endothelium in vivo. The
working concept is that endothelial cell retraction leads to expo-
sure of underlying basement membrane, and consequently to
activation of coagulation as well as a loss of the barrier function of
the endothelium. This process is a reasonable model for how
hyperacute rejection occurs. The endothelial cells lining the graft
aren't lysed by antibody and complement, but they do retract a bit,
and interstitial hemorrhages ensue. The hemorrhaging, for exam-
ple, leads to rejection of the heart, since it cannot contract against
the engorged tissue, thereby resulting in rapid graft failure. It
might be of therapeutic significance if we could block such
endothelial cell responses, even in the context of hyperacute
rejection. In-vitro studies by Saadi and Platt suggest that C5a is
the key to endothelial cell retraction [56]. Other data from that
laboratory indicate that the levels of complement on the endo-
thelial membrane are limiting, and that the initial endothelial cell
retraction can he reversed and the endothelial cells can repair the
complement-induced damage [56]. On the other hand, C5a-
induced loss of endothelial cell heparan sulfate in the early
post-transplant period is, to my mind, of minimal mechanistic
significance, given the studies to date.
DR. RONALD D. PERRONE (Division of Nephrology, New England
Medical Center): You spoke of the great expense of genetically
engineering individual pigs to represent a particular human
recipient. Would it be possible to genetically engineer a pig or
other suitable donor to have a null expression of MHC?
DR. HANCOCK: One aspect of that would be targeting the pig
MHC system. If long-term survival can be achieved, and especially
if there is shedding of MHC antigens and uptake of the host
immune system, that is, if indirect xenorecognition is occurring,
minimizing or altering that process might be useful. There is some
interest in targeting the pig MHC class-I expression; beta-2 in the
pig has been cloned. We can try to target or knock out that gene.
Class II, unlike in humans, is quite restricted in its expression in
pigs and might be less important than targeting MHC class-I.
DR. HARRINGTON: Wayne, you mentioned the phrase accom-
modation. I understand politically and biologically what suppres-
sion and tolerance mean, but I've never quite understood accom-
modation. Could you explain the biologic meaning of
accommodation, first the concept and then the mechanisms that
underlie it?
DR. HANCOCK: This is where I wish Fritz Bach would jump up
and take over the microphone. He suggested some years ago that
"accommodation" be used to denote the process by which graft
endothelial cells on the membrane might somehow be protected
against gradually rising levels of complement and/or antibody that
are otherwise toxic or lytic. If these mediators were assembled
rapidly, they caused endothelial retraction and graft injury. If their
assembly occurs on a slow basis, after being depleted for some
time, the endothelial cells become resistant or refractory to
humoral attack.
At the 1996 American Society of Transplant Physicians meeting
in Dallas, Texas, we presented data from our ongoing studies in
the hamster-to-rat cardiac xenograft model [57]. Let me offer our
current concepts. Brief depletion of complement, followed by its
gradual return, is associated with long-term survival, despite the
continuing deposition of immunoglobulins and complement acti-
vation along the surfaces of graft endothelial cells. At least part of
this effect might be due to selective alterations in the humoral
response. We are focusing on the importance of IgG2c, as is Barry
Kahan, whose group also reported a selective IgG2c response
after rapamycin therapy in rat allograft models [581. Our rat
model yielded two exciting additional and unforeseen aspects to
accommodation, although their relative importance remains un-
clear. First, these accommodated xenografts are infiltrated by
large numbers of TH2 cells, that is, CD4+ T-cells and macro-
phages producing large amounts of IL-4, IL-JO, and IL-13, but
little or no IL-2, IFN-y or pro-inflammatory cytokines such as
TN F-u [58]. This population might induce our second key finding,
namely, that accommodated xenografts have high levels of "pro-
tective" genes, including anti-apoptotic and anti-oxidant genes
[571. In addition, the skewed host immune response might explain
our finding that second xenografts in accommodated recipients
are not subject to rejection, nor are accommodated xenografts
that are exposed to hyperimmune serum. Clearly, the investiga-
tioris underway need to establish the extent to which these
endothelial genes induced in accommodated grafts mediate the
survival rates obtained, despite the surface-bound antibody and
complement. Similarly, the role of TH2 cytokines in inducing this
response should be investigated.
DR. MADIAs: You referred from time to time to different
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organs. Are there substantial differences in the host's response to
xenotrarisplaritation of kidney versus heart versus liver?
DR. HcocK: I talked primarily about revascularized trans-
plants. The transplantation of islets, neurons, etc. is a whole
different field. In fact, in Boston pig neurons have been trans-
planted into patients with various degenerative neural diseases
[51 In terms of organ differences, the heart is more susceptible to
hyperacute rejection than the kidney, which is itself an order of
magnitude more susceptible than the liver. The liver is quite
resistant to hyperacute rejection. In the species combination in
which the heart survives 10 minutes, the kidney might survive up
to an hour, and the liver 12 to 20 hours. This difference is
comparable to allografts, in that liver allografts can sustain a more
extensive humoral response than other transplants.
DR. SINGH: You alluded to the pivotal importance of antibodies
to carbohydrate moieties in the hyperacute rejection phase. To
adequately study this problem, experiments in humans and pri-
mates are necessaty, while studies in rodents, although interest-
ing, are of limited applicability. How are you and other workers in
the field addressing this problem?
DR. HANCOCK: Potential solutions are galactosyl transferase
knockout in the pig, and/or development of H-transferase trans-
geneic pigs. In the interim, plasmapheresis or organ absorption,
administration of soluble disaccharides, or absorption over col-
umns are being used. The practical solution at this time is blocking
the complement pathway using organs from pigs transgenic for
human RCAs. Whilst the other research goes on, development of
strategies for overcoming delayed xenograft rejection is, in my
opinion, the key issue in the field right now.
Reprint requests to Dr. W W Hancock, Sandoz Center for Immunobiology,
New England Deaconess Hospital, Harvard Medical School, 99 Brookline
Avenue, Boston, Massachusetts 02215, USA
Note added in proof
Recent data from Hamann et al [HAMANN J, VOGEL B, VANSCHIJNDEL
GMW, VANLIER RAW: The seven-span transmembrane receptor CD97
has a cellular ligand (CD55, DAF). J Exp Mcd 184:1185—1189, 19961 show
that CD55 is a high-affinity ligand for the seven-span transmembranc
molecule, CD97, which is rapidly expressed upon activation of many
leukocytes, particularly monocytes and NK cells. Hence, genetic engineer-
ing of pig organs to express human RCA such as CD55, although
abrogating HAR, itself might predispose to development of DXR. Such
data re-emphasize the need for careful development and detailed analysis
of possible unexpected effects of transgenes, well before clinical trials,
currently being advocated by some on the basis of in vitro and limited in
vivo data, are justified.
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